Stem cell treatments could come by 2005

韩雪娜

日期: 2002-10-25 今日/总浏览: 1/15624 r6 H0 Z6 H! n/ a( a) L" l

6 V9 T- V6 ?* c# ?* \7 \4 m, W5 I
# m3 f- M8 T7 E* w3 F( M" i6 Y3 h, D' T' e6 \" q3 A8 o3 f6 x
, v* ?( L/ m$ s' T4 g
Thefirstcommerciallyavailablestemcell-derivedproductslikelywillcomefromadultstemcellsandbeforthetreatmentofneurologicaldisorderssuchasParkinson'sandAlzheimer'sdisease,theheadofanadultstemcellcompanytoldUnitedPressInternational.
( `$ M2 }/ B" `6 x  @/ F4 cTheproductscouldbeavailableinthenextthreeyears,saidMartinMcGlynn,presidentandchiefexecutiveofficerofStemCellsInc.,ofPaloAlto,Calif.,whichisworkingtodevelopmedicaltreatmentsderivedfromadultstemcells.McGlynnwasexpectedtomakesimilarremarksatTechvest's4thAnnualHealthcareConference&ExpoinBostonWednesday.1 Z0 L6 x( [6 ^
Stemcellshavetheabilitytogiverisetodifferentcelltypesinthebody.Theyhavethepotentialtoreplacetissuesdamagedbydisease.
; M& X- y& p; ?# n! ~: U; Q$ a9 T; `) SEmbryonicstemcellscangiverisetoanycelltypeandthushavethegreatestpotentialtotreatthewidestrangeofdiseases.However,theyarecontroversialbecauseharvestingthemrequiresthedestructionofembryos.Adultstemcells,whichcanbederivedfromadulttissueswithoutharmingthedonor,offeralesscontroversialalternative,althoughtheycangiveriseonlytoalimitednumberofcelltypes.
; s9 x2 D: e3 GMypredictionisthat...we'relikelytoseeoneortwostemcellproductsonthemarketinthisdecade,McGlynnsaid.Productsderivedfromadultstemcellsarelikelytobethefirstproductsbecausethesearefurtheralonginthedevelopmentprocessanddon'thavealltheregulatoryhurdlesthatareassociatedwithembryonicstemcells,hesaid.7 e! V3 D! W$ W3 g* y
Suchproductsprobablywillappearonthemarketstartingfromaround2005andcontinuinginthebackhalfofthisdecade,hesaid.
1 u  [5 C$ I. L" V: L' D5 jMcGlynnpredictedthefirstproductswouldbetreatmentsfordegenerativediseasesofthecentralnervoussystem,includingParkinson's,Alzheimer's,strokeandparalysis.6 C! y8 Y, }1 e, d
Iwouldagreewith(McGlynn)thatsomeoftheearliestproductstoreachcommercializationwillbeforneurologicaldisorders,LindaPowers,managingdirectorofToucanCapital,aventurecapitalfirminBethesda,Md.,toldUPI.It'sstillupintheairwhether(thefirstproducts)willbeadultorembryonicstemcells,addedPowers,whosefirmhasmadeinvestmentsinbothadultandembryonicstemcellcompanies./ i( ~8 m2 _& n& w
Wereallyarelookingacrosstheboardatadultandembryonicstemcells,Powerssaid.We'renottiltingonewayortheother.Wewanttoseewhatlookslikeitproducesthebestresultsandgofromthere.It'stooearlytotellwhichlineofcellswillbethefirsttoreachthemarket,sheadded.
/ d8 m% M5 ^4 o! p" Z" wMcGlynnsaidheexpectsembryonicstemcellseventuallytobecommercializedaswell.Subjecttotheavailabilityofcapital,Iwouldanticipateembryonicstemcellsciencewillcontinuetobeworkedonandimproved,hesaid.Overtime,scientistsmightlearnhowtofullyunlockthepotentialofembryonicstemcellsanddevelopthemasdiseasetreatments,hesaid.' ~% i% B) R) W1 V% Q
Dependingoneconomicsandthedisease-treatingcapabilityofeachcellline,McGlynnadded,Wecouldhaveboth(adultandembryonicstemcell-derivedproducts)outthereonthemarket.
4 h: B9 R% M& P$ \0 s$ G) W( s7 L
! Z, G( l; G3 N" r
3 L# [, K0 G2 h  t+ G" H4 S# S) ]* q9 L5 h
# @, B* v; S" z* Q5 x9 ~

0 C9 [  u4 H9 h; `" _; N, T1 R6 P& s作者: Steve Mitchell7 ?& A/ j/ m* f9 {+ Q; o) x. l
来源: UPI Medical Correspondent
/ k" i( ?* s: L: I发布者: 刘斌